CYTK
Cytokinetics Inc Health Care Pharmaceutical Preparations Russell 3000
$62.99Close
$7.7BMarket cap
$59.19 – $87.2652-week range
Nov 4, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 32 · weaker than 68% of stocks over 12 months
- Far from its high 28% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
up 2.9%
price change
1mo
down 4.4%
price change
12-month return
up 1%
market up 11% ·
its own down 9%
F-score
—
— Not assessed
Altman Z
-1.95
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 7.8%
EBIT / enterprise value
Cheaper than
10%
of the market · expensive
Revenue growth
up 377%
year on year
EPS growth
—
latest quarter
Sales growth
down 57%
latest quarter · -1183 pts
ROE
—
return on equity
Free cash margin
down 607%
-$534.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
3.3%
$2.05 a day · 2×ATR $58.90
RS
32 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.64
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$659.6M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 4.0% over the year, from 118m to 123m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-3% vs market2 sessions after results
Financials
- Net -892%
- Free cash -607%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $55.8M | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Operating income | -$93.9M | -$186.3M | -$324.2M | -$496.2M | -$536.2M | -$612.3M |
| Net income | -$127.3M | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| Net margin | -228% | -306% | -411% | -6989% | -3191% | -892% |
| Earnings per share | -$1,972.75 | -$2,800.43 | -$4,330.14 | -$5,451.95 | -$5,264.61 | -$6,535.68 |
| Free cash flow | -$2.1M | -$191.4M | -$310.9M | -$415.7M | -$399.8M | -$534.8M |
| Free cash margin | -4% | -272% | -329% | -5521% | -2164% | -607% |
| Cash | $83.0M | $112.7M | $65.6M | $113.0M | $94.9M | $122.5M |
| Long-term debt | $46.2M | $47.4M | $63.8M | $58.4M | $93.2M | $246.4M |
| Shareholders' equity | $113.4M | $243.9M | -$107.9M | -$386.3M | -$135.4M | -$659.6M |
| Shares outstanding | 71.02m | 84.80m | 94.83m | 101.64m | 118.21m | 122.94m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 10, 2024 | Quarterly ↗ | Mar 31, 2024 | 40d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 28, 2026 | Other events ↗ |
| Aug 13, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| May 27, 2026 | Shareholder vote ↗ |
| May 8, 2026 | Other events ↗ |
| May 5, 2026 | Other events ↗ |
| May 5, 2026 | Results ↗ |
| Feb 24, 2026 | Results ↗ |
| Feb 17, 2026 | Other events ↗ |
| Dec 19, 2025 | Other events ↗ |
| Dec 12, 2025 | Other events ↗ |
| Nov 14, 2025 | Director or officer change ↗ |